Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Immunity Cells in Blood (Innate Immunity Signal Transduction in Human Leukocytes)

Study Background

This study is no longer accepting participants.

To find studies that are currently recruiting, please visit the Join an NIEHS Study website

For More Information

The Innate Immunity Signal Transduction in Human Leukocytes is a research study to determine the response of immune cells from the bloodstream.

This study will investigate the response of immune cells to various signals in the test tube to determine how they sense the signals in the body and what substances they produce in response to them. It will determine how the cells may, under certain circumstances, contribute to inflammation, and will measure substances in the blood plasma (the liquid, non-cellular part of the blood) that might stimulate white blood cells, in order to understand how the blood responds to possible disease-related conditions.

Eligibility Criteria

  • Healthy men and non-pregnant women aged 18-65
  • Weighing at least 110 pounds
  • Normal, healthy adult donors as judged by screening questionnaire
  • Nonpregnant
  • HIV negative (proof required every 6 months we will conduct test)
  • Hepatitis B surface antigen and hepatitis C serology negative (checked every 6 months we will conduct test)
    • The rationale for HIV and hepatitis viral testing is that chronic viral infection may alter and possibly invalidate our experimental results. HIV and hepatitis results will be confidentially obtained. Testing will be contracted to an external certified laboratory and will be paid for by the study group. Results will be available only to the study doctor/PI (Fessler), the study coordinator, the CRU Director (Garantziotis, LAI), and the donor, with the few caveats that follow

Principal Investigator

Michael B. Fessler, M.D.
Michael B. Fessler, M.D.
Chief, Immunity, Inflammation, and Disease Laboratory and Principal Investigator
Tel 984-287-4081
fesslerm@niehs.nih.gov
Curriculum Vitae Michael Fessler (377KB)
NIH Intramural Profile Michael Fessler
P.O. Box 12233
Mail Drop D2-01
Durham, N.C. 27709
Stavros Garantziotis, M.D.
Stavros Garantziotis, M.D.
Medical Director, NIEHS Clinical Research Unit
Tel 984-287-4412
Fax 919-541-9854
garantziotis@niehs.nih.gov
Curriculum Vitae (80KB)
P.O. Box 12233
Mail Drop CU-01
Durham, N.C. 27709
Back
to Top